LATISSE® solution is a growth treatment for hypotrichosis (inadequate or not enough eyelashes). In fact, it's the first FDA-approved treatment clinically proven to grow lashes. And it's the first lash growth product of its kind available by prescription.
LATISSE® grows lashes longer, fuller and darker.
LATISSE® solution is a once-nightly treatment you apply topically to the base of your upper eyelashes, as instructed by your doctor. Then, gradually, the results come in. You may start to see more length in as little as 4 weeks and you should achieve full growth in 16 weeks. It’s not an illusion of growth. It’s real lash growth.
How LATISSE® works.
LATISSE® makes lash growth possible because of its active ingredient: bimatoprost. Although the precise mechanism of action is unknown, LATISSE® is believed to affect the growth (anagen) phase of the eyelash hair cycle in two ways: first, it increases the length of this phase, and second, it increases the number of hairs in this growth phase.
The history behind LATISSE®.
LATISSE® was created by Allergan. In 2001, Allergan developed a medicated eye drop to treat elevated intraocular pressure. Many patients using this medication also began to grow longer, fuller and darker lashes as a side effect. This led Allergan to study the medication's active ingredient, bimatoprost, specifically for growing lashes. After a clinical trial, LATISSE® was approved by the FDA in December of 2008.
WHAT ARE THE RISKS and POSSIBLE SIDE EFFECTS OF USING LATISSE™?
1. The following side effects are the most frequently reported, but occur in less than 4% of users (i.e. 4 out of 100 users):
a. Eye irritation and itching
b. Conjunctival hyperemia or red eye (redness of the white, moist covering of the eyeball)
c. Dry eye symptoms
d. Eyelid redness
2. Although rare, Latisse™ has the potential to permanently increase the brown pigmentation of the iris (colored part of the eyeball, inside the eye).
3. Latisse™ may cause hyperpigmentation or darkening of the eyelid skin which may or may not be reversible upon discontinuation of the treatment.
4. Latisse™ may lower intraocular pressure (IOP) or pressure inside the eye; however, the magnitude of this reduction is usually not a cause for concern.
a. If you have a history of abnormal eye pressures or glaucoma you should only use Latisse™ under the close supervision of your ophthalmologist.
b. Inform anyone conducting an eye pressure examination that you are using Latisse™.
5. You should inform your ophthalmologist that you are using Latisse™ if eye surgery is planned.
6. Do not use Latisse™ if you are allergic or hypersensitive to bimatoprost (LumiganR) or any other ingredient in this product.
7. Latisse™ is intended for use on the skin at the base of the eyelashes of the UPPER eyelids only.
8. DO NOT APPLY to the lower eyelids as this will increase the chance of side effects such as hyperpigmentation or darkening of the eyelid skin.
9. You should discontinue use of Latisse™ and call your physician immediately if you develop an eye infection, sudden decrease in vision, suffer eye trauma, or develop eye or eyelid reactions.
WHAT ARE THE CONTRAINDICATIONS OF USING LATISSE™?
You should NOT use Latisse™ if: you are allergic or hypersensitive to bimatoprost (LumiganR) or any other ingredient in this product; are about to undergo cataract or other eye procedures, have an intraocular inflammation (uveitis), have risk factors for macular edema, have an eye infection, or are being treated for glaucoma with eye drops, unless cleared by your treating ophthalmologist. LATISSE™ is not approved for people under the age of 18. It is not recommended for pregnant or lactating women.
PATIENT’S ACCEPTANCE OF RISKS
I have read the above information and I understand that it is impossible for the the establishment to inform me of every possible complication that may occur. I am aware that results cannot be guaranteed. By signing below, I agree that the establishment has answered all of my questions and I give informed consent to proceed with Latisse™ treatment.